Site-specific O-GlcNAc MAbs: New Tools for Glycoproteomics
位点特异性 O-GlcNAc MAb:糖蛋白组学的新工具
基本信息
- 批准号:8395145
- 负责人:
- 金额:$ 32.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-17 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcetylglucosamineAffinityAntibodiesAntigensApoptoticAutoantigensBasic ScienceBiologicalCarbohydratesCell physiologyComplexCytoplasmic ProteinDetectionDiabetes MellitusDiseaseEnzymesEpitopesGenetic TranscriptionGluconeogenesisGlycopeptidesHarvestHeartHumanHybridomasImmune systemImmunizationInjectableInsulinInsulin ResistanceLeadLettersLibrariesLinkModificationMonoclonal AntibodiesMusNuclear ProteinsPhasePhospho-Specific AntibodiesPhosphorylationPlayPolysaccharidesPost-Translational Protein ProcessingPreparationProcessProductionProtein-Carbohydrate InteractionProteinsReagentRegulationResearchResearch PersonnelResourcesRoleScientistScreening procedureSerineSignal TransductionSiteSpecificityStimulusSynthetic VaccinesSystemTestingThreonineTumor Suppressor GenesUDP-N-acetylglucosamine-peptide beta-N-acetylglucosaminyltransferaseUniversitiesWestern Blottingbiological systemscandidate selectioncostglycosylationimmunogenicitymedical schoolspeptide O-linked N-acetylglucosamine-beta-N-acetylglucosaminidasepeptide structureprofessorprotein aminoacid sequenceresponsetool
项目摘要
DESCRIPTION (provided by applicant): O-glycosylation of serine and threonine of nuclear and cytoplasmic proteins by a single beta-N- acetyl-D-glucosamine moiety (O-GlcNAc) is a ubiquitous post-translational modification that is highly dynamic and fluctuates in response to cellular stimuli. O-GlcNAc often competes with protein phosphorylation, and these two modifications have extensive crosstalk in the regulation of signaling, transcription, and the functions of oncogenes and tumor suppressors. Diabetes, the biological driver for this application, is a prime example of a disease where increased levels of insulin resistance, inhibition of the anti-apoptotic action of insulin, alteration of circulating O-GlcNAc is known to disrupt normal signaling, and has been associated with the induction of adipocytokine levels, deregulation of gluconeogenesis, and modulation of insulin gene transcription. We will utilize a new immunogen strategy to develop site-specific O-GlcNac antibodies to four sites of O-GlcNAc modification on three proteins that play a role in signaling suppression in diabetes. Consequently, if we are successful, the mAbs generated in this initial study will have an immediate impact on diabetes research in addition to providing a test system for this strategy. We predict that at the end of phase 1, we will have demonstrated a strategy that will allow GlycoScientific to produce a wide range of O-GlcNAc site-specific MAbs, at a known and contained cost. We feel that these will have far reaching implications in disease research.
PUBLIC HEALTH RELEVANCE: O-glycosylation of serine and threonine of nuclear and cytoplasmic proteins by a single beta-N- acetyl-D-glucosamine moiety (O-GlcNAc) is a ubiquitous post-translational modification that is highly dynamic and fluctuates in response to cellular stimuli. O-GlcNAc often competes with protein phosphorylation, and these two modifications have extensive crosstalk in the regulation of signaling, transcription, and the functions of oncogenes and tumor suppressors. Diabetes, the biological driver for this application, is a prime example of a disease where increased levels of insulin resistance, inhibition of the anti-apoptotic action of insulin, alteration of circulating O-GlcNAc is known to disrupt normal signaling, and has been associated with the induction of adipocytokine levels, deregulation of gluconeogenesis, and modulation of insulin gene transcription. We will utilize a new immunogen strategy to develop site-specific O-GlcNac antibodies to four sites of O-GlcNAc modification on three proteins that play a role in signaling suppression in diabetes. Consequently, if we are successful, the mAbs generated in this initial study will have an immediate impact on diabetes research in addition to providing a test system for this strategy.
描述(由申请人提供):单个β - n -乙酰- d -氨基葡萄糖片段(O-GlcNAc)对细胞核和细胞质蛋白的丝氨酸和苏氨酸的o -糖基化是一种普遍存在的翻译后修饰,它是高度动态的,并且在细胞刺激下波动。O-GlcNAc经常与蛋白磷酸化发生竞争,这两种修饰在调控信号、转录以及癌基因和肿瘤抑制因子的功能方面存在广泛的串扰。糖尿病是这一应用的生物学驱动因素,是胰岛素抵抗水平升高、胰岛素抗凋亡作用抑制、循环O-GlcNAc改变已知会破坏正常信号的疾病的主要例子,并且与脂肪细胞因子水平的诱导、糖异生的解除和胰岛素基因转录的调节有关。我们将利用一种新的免疫原策略来开发位点特异性的O-GlcNac抗体,这些抗体针对三种在糖尿病信号抑制中起作用的O-GlcNac修饰蛋白的四个位点。因此,如果我们取得成功,除了为该策略提供测试系统外,在这项初步研究中产生的单克隆抗体将对糖尿病研究产生直接影响。我们预测,在第一阶段结束时,我们将展示一种策略,使糖科学公司能够以已知和可控的成本生产广泛的O-GlcNAc位点特异性单克隆抗体。我们认为这些将对疾病研究产生深远的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RON ORLANDO其他文献
RON ORLANDO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RON ORLANDO', 18)}}的其他基金
Isotopically Labeled Heparan Sulfate Glycosaminoglycan Disaccharides for use as Internal Standards
用作内标的同位素标记硫酸乙酰肝素糖胺聚糖二糖
- 批准号:
10080563 - 财政年份:2020
- 资助金额:
$ 32.27万 - 项目类别:
CREATING ANTIBODIES TO ENABLE THE STUDY OF MYCOBACTERIUM TUBERCULOSIS INFECTIONS IN GUINEA PIGS
创造抗体以研究豚鼠结核分枝杆菌感染
- 批准号:
10027950 - 财政年份:2019
- 资助金额:
$ 32.27万 - 项目类别:
Generation of antibodies to monitor Notch O-fucosylation in vivo
生成用于监测体内 Notch O-岩藻糖基化的抗体
- 批准号:
9200115 - 财政年份:2016
- 资助金额:
$ 32.27万 - 项目类别:
Development of Isotopically Labeled Glycoproteins for use as Internal Standards
开发用作内标的同位素标记糖蛋白
- 批准号:
9908593 - 财政年份:2015
- 资助金额:
$ 32.27万 - 项目类别:
Development of Isotopically Labeled Glycoproteins for use as Internal Standards
开发用作内标的同位素标记糖蛋白
- 批准号:
8834650 - 财政年份:2015
- 资助金额:
$ 32.27万 - 项目类别:
Site-specific O-GlcNAc MAbs: New Tools for Glycoproteomics
位点特异性 O-GlcNAc MAb:糖蛋白组学的新工具
- 批准号:
8546432 - 财政年份:2012
- 资助金额:
$ 32.27万 - 项目类别:
GLYCOPROTEIN GLYCOMICS: EXPRESSION IN MOUSE ES CELLS & PROGENY
糖蛋白糖组学:小鼠 ES 细胞中的表达
- 批准号:
8363005 - 财政年份:2011
- 资助金额:
$ 32.27万 - 项目类别:
COMPARATIVE PROTEOMICS AND GLYCOPROTEOMICS OF PROTEINS SECRETED FROM B CINEREA
灰霉病菌分泌蛋白质的比较蛋白质组学和糖蛋白质组学
- 批准号:
8363013 - 财政年份:2011
- 资助金额:
$ 32.27万 - 项目类别:
DEVELOPMENT OF TECHNIQUES FOR QUANTITATIVE GLYCOMICS
定量糖组学技术的发展
- 批准号:
8363021 - 财政年份:2011
- 资助金额:
$ 32.27万 - 项目类别:
PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS-ASSOCIATED GLYCANS
猪繁殖
- 批准号:
8363119 - 财政年份:2011
- 资助金额:
$ 32.27万 - 项目类别:
相似海外基金
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
- 批准号:
10549640 - 财政年份:2023
- 资助金额:
$ 32.27万 - 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
- 批准号:
2750554 - 财政年份:2021
- 资助金额:
$ 32.27万 - 项目类别:
Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
- 批准号:
61319 - 财政年份:2020
- 资助金额:
$ 32.27万 - 项目类别:
Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10013588 - 财政年份:2020
- 资助金额:
$ 32.27万 - 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
- 批准号:
20K07009 - 财政年份:2020
- 资助金额:
$ 32.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
- 批准号:
10603473 - 财政年份:2020
- 资助金额:
$ 32.27万 - 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
- 批准号:
2342674 - 财政年份:2020
- 资助金额:
$ 32.27万 - 项目类别:
Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
- 批准号:
10117194 - 财政年份:2020
- 资助金额:
$ 32.27万 - 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10115604 - 财政年份:2020
- 资助金额:
$ 32.27万 - 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
- 批准号:
10294224 - 财政年份:2018
- 资助金额:
$ 32.27万 - 项目类别: